Funding for new drug development targeting neglected diseases is stagnant and insufficient. In the last four years the lack of approvals of new molecular entities and biologics is conspicuous.
Drug Development For Neglected Diseases Has Stagnated
Funding for new drug development targeting neglected diseases is stagnant and insufficient. In the last four years the lack of approvals of new molecular entities and biologics is conspicuous.